Management of small HER2-positive breast cancers

The Lancet Oncology

Volumn 11, Issue 12, 2010, Pages 1193-1199

  Banerjee, Susana ^a   Smith, Ian E ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; MONOTHERAPY; NOTE; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TUMOR VOLUME;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 78649588945     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70119-4     Document Type: Note

References (44)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTG).
2. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002, 20:4141-4149.
3. Fracheboud J, Otto SJ, van Dijck JA, Broeders MJ, Verbeek AL, de Koning HJ Decreased rates of advanced breast cancer due to mammography screening in the Netherlands. Br J Cancer 2004, 91:861-867.
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
5. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
7. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
9. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
10. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study. San Antonio Breast Cancer Symposium; San Antonio, TX, USA, 2008. Abstr 62.
11. Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009, 27:6129-6134.
12. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007, 7:153.
13. Costa RB, Kurra G, Greenberg L, Geyer CE Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer. Ann Oncol 2010, published online March 29. 10.1093/annonc/mdg096.
14. Rosen PP, Groshen S, Kinne DW, Norton L Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993, 11:2090-2100.
15. Rosen PR, Groshen S, Saigo PE, Kinne DW, Hellman S A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989, 7:355-366.
16. Colleoni M, Rotmensz N, Peruzzotti G, et al. Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol 2004, 15:1633-1639.
17. Rosner D, Lane WW Should all patients with node-negative breast cancer receive adjuvant therapy? Identifying additional subsets of low-risk patients who are highly curable by surgery alone. Cancer 1991, 68:1482-1494.
18. Joensuu H, Pylkkanen L, Toikkanen S Late mortality from pT1N0M0 breast carcinoma. Cancer 1999, 85:2183-2189.
19. Arnesson LG, Smeds S, Fagerberg G Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10 mm or less detected clinically and by screening. Eur J Surg 1994, 160:271-276.
20. Leitner SP, Swern AS, Weinberger D, Duncan LJ, Hutter RV Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0). Cancer 1995, 76:2266-2274.
21. Lee AK, Loda M, Mackarem G, et al. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome. Cancer 1997, 79:761-771.
22. Mann GB, Port ER, Rizza C, Tan LK, Borgen PI, Van Zee KJ Six-year follow-up of patients with microinvasive, T1a, and T1b breast carcinoma. Ann Surg Oncol 1999, 6:591-598.
23. Moon TE, Jones SE, Bonadonna G, et al. Development and use of a natural history data base of breast cancer studies. Am J Clin Oncol 1987, 10:396-403.
24. Stierer M, Rosen HR, Weber R, Marczell A, Kornek GV, Czerwenka E Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. Surg Gynecol Obstet 1992, 175:151-160.
25. Ichizawa N, Fukutomi T, Iwamoto E, Akashi-Tanaka S Long-term results of T1a, T1b and T1c invasive breast carcinomas in Japanese women: validation of the UICC T1 subgroup classification. Jpn J Clin Oncol 2002, 32:108-109.
26. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol 1995, 13:1144-1151.
27. Chia SK, Speers CH, Bryce CJ, Hayes MM, Olivotto IA Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. J Clin Oncol 2004, 22:1630-1637.
28. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008, 26:5697-5704.
29. Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003, 9:923-930.
30. Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG, Edwards J Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 2009, 100:680-683.
31. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009, 27:5700-5706.
32. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009, 27:5693-5699.
33. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
34. Untch M, Gelber RD, Jackisch C, et al. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008, 19:1090-1096.
35. Slamon D, Eiermann W, Robert N, et al. 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/ETH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium; San Antonio, TX, USA, 2006. Abstr 52.
36. McArthur HL, Morris PG, Patil S, et al. Benefits of trastuzumab-based therapy for women with small, node-negative, HER2-positive breast cancer. ASCO Breast Cancer Symposium 2009; abstr 228.
37. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, et al. Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: a joint AERIO/REMAGUS study. Proc Am Soc Clin Oncol 2009, 27:517. (abstr).
38. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329.
39. Kataja V, Castiglione M Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009, 20:10-14.
40. National Comprehensive Cancer Network (NCCN) Guidelines, (accessed May 1, 2010). http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
41. NIH guidelines National Institute of Health, (accessed June 17, 2010). http://www.cancer.gov/cancertopics/pdq/treatment/breast/HealthProfessional/page7#Section_183.
42. Anon. What clinicians want to know: addressing the most common questions and controversies in the current clinical management of breast cancer. Research to Practice Satellite Symposium at the 32nd Annual San Antonio Breast Cancer Symposium. 2009.
43. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009, 27:5529-5537.
44. Knauer M, Cardoso F, Mook S, et al. Identification of a low risk subgroup in Her2-positive breast cancer by the 70-gene prognosis signature. San Antonio Breast Cancer Symposium; San Antonio, TX, USA; 2008. Abstr 4171.